Cell-Based Combos Should Go Through CBER For Non-Wound Uses – PhRMA
Executive Summary
Cell-based combination therapies should be reviewed by the Center for Biologics Evaluation & Research for indications other than wound healing, Pharmaceutical Research & Manufacturers of America Biologics & Biotechnology/Preclinical Affairs Research Director Sara Radcliffe said June 24